$119.23
▲ $0.77 (+0.7%)
MNPR
Monopar Therapeutics Inc.
Investor Score
59C
Moderate rating
Based on 6 of 7 weighted categories, computed from real, live financial data only.
77
Technical
46
Fundamental
63
Growth
50
Fair Value
50
News
—
Quality
48
Risk
Want the full breakdown — DCF fair value, technical indicators, news sentiment, and an AI-written narrative explaining this score?
View the full analysis (Hebrew) ←All raw data comes from real commercial financial data providers. This page is for educational purposes only and is not investment advice.